Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloma X Relapse (Intensive)
NCT00747877Phase 3Unknown
- Sponsor
- Leeds Cancer Centre
- Start
- Apr 2008
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melphalan in multiple myeloma (MM) (2 arms), sponsored by Leeds Cancer Centre. Primary endpoint: Time to disease progression. Status: unknown.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00747877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00747877.